The global veterinary/animal vaccine market size was estimated to be USD 12.95 billion in 2023 and is expected to reach at USD 35.11 billion by 2033 with a CAGR of 9.48% during the forecast period 2023-2033. Rising cattle disease outbreaks, rising worries about food security, rising animal husbandry, rising demand for animal products, rising introduction of technologically advanced vaccines, rising prevalence of zoonotic diseases, rising improved demand for animal protein, rising government support initiatives, rising prevalence of respiratory diseases in animals, and rising research activities for the development of novel vaccines are the key factors propelling the market growth.
Increasing launch of novel vaccines is predicted to fuel the market growth during the forecast period. For instance, in May 2022, Zoetis launched the Poulvac Procerta HVT-IBD vaccine, designed to safeguard chickens from infectious bursal disease (IBD), thereby expanding its range of recombinant vector vaccines.
By product, inactivated vaccine was the highest revenue-grossing segment in the global veterinary/animal vaccine market in 2022 owing to rising prevalence of infectious diseases, growing demand of vaccines, increasing launch of advanced vaccines. For instance, in January 2021, The Poulvac Procerta HVT-IBD vaccine was released by Zoetis to protect poultry against Infectious Bursal Disease (IBD). This expands the company's range of recombinant vector vaccines. Additionally, attenuated live vaccines is predicted to grow at fastest CAGR during the forecast period owing to the increasing development of protein subunit vaccines.
By animal, companion was the highest revenue-grossing segment in the global veterinary/animal vaccine market in 2022 owing to increasing prevalence of zoonotic diseases in humans, rising awareness about vaccination, and surge in number of pets & pet owners, and growing product approvals by regulatory bodies. For instance, in February 2020, Zoetis has obtained approval from the US FDA for Simparica, a monthly chewable medication for dogs. This medication effectively treats heartworm disease and provides protection against fleas and ticks. Additionally, Livestock is predicted to grow at fastest CAGR during the forecast period owing to the growing livestock population, rising government initiatives, and surge in outbreak of diseases among cattle and sheep.
By route of administration, subcutaneous was the highest revenue-grossing segment in the global veterinary/animal vaccine market in 2022 owing to their benefits such as subcutaneous route of administration is quicker and less painful for animals. Additionally, intranasal is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of respiratory diseases in animals and increasing research & development activities by market players for the development of better vaccines, and growing introduction of new products. For instance, in February 2020, MSD Animal Health (Merck Animal Health) has recently introduced Nasalgen, an intranasal inoculation product designed to safeguard beef and dairy cattle against viral pathogens that cause pneumonia.
By end-user, veterinary clinics was the highest revenue-grossing segment in the global veterinary/animal vaccine market in 2022 owing to the increasing prevalence of infectious diseases among animals and rising initiatives by key market players such as mergers & acquisitions. For instance, in September 2022, Zoetis has completed the acquisition of Jurox, a privately-owned animal health company specializing in the development, manufacturing, and marketing of a diverse portfolio of veterinary medicines for the treatment of both livestock and companion animals. Additionally, veterinary hospitals is predicted to grow at fastest CAGR during the forecast period owing to the sure in number of pet owners visiting hospitals with their pets.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of livestock, increasing zoonotic diseases, presence of well-established pharmaceutical companies, rising cases of canine disorders, surge in adoption of vaccination for the same, growing pet population in the U.S., and increasing research & development activities. For instance, in February 2021, Ceva has formed a partnership with the French National Research Institute for Agriculture, Food, and Environment (INRAE) to conduct research and development in the field of preventing infectious diseases originating from animals and enhancing animal health. Additionally, Asia Pacific is predicted to grow at fastest CAGR during the forecast period owing to the increasing companion animal population, rising demand for animal-based products, growing adoption of veterinary vaccines, surge in government initiatives, increasing research & development expenditures, and rising introduction of new products. For instance, in November 2020, HIPRA Indonesia has recently conducted a virtual launch for GUMBOHATCH, an advanced immune complex immunization product for broiler chickens, designed to combat Infectious Bursal Disease.
Increasing launch of novel vaccines is predicted to fuel the market growth during the forecast period. For instance, in May 2022, Zoetis launched the Poulvac Procerta HVT-IBD vaccine, designed to safeguard chickens from infectious bursal disease (IBD), thereby expanding its range of recombinant vector vaccines.
By product, inactivated vaccine was the highest revenue-grossing segment in the global veterinary/animal vaccine market in 2022 owing to rising prevalence of infectious diseases, growing demand of vaccines, increasing launch of advanced vaccines. For instance, in January 2021, The Poulvac Procerta HVT-IBD vaccine was released by Zoetis to protect poultry against Infectious Bursal Disease (IBD). This expands the company's range of recombinant vector vaccines. Additionally, attenuated live vaccines is predicted to grow at fastest CAGR during the forecast period owing to the increasing development of protein subunit vaccines.
By animal, companion was the highest revenue-grossing segment in the global veterinary/animal vaccine market in 2022 owing to increasing prevalence of zoonotic diseases in humans, rising awareness about vaccination, and surge in number of pets & pet owners, and growing product approvals by regulatory bodies. For instance, in February 2020, Zoetis has obtained approval from the US FDA for Simparica, a monthly chewable medication for dogs. This medication effectively treats heartworm disease and provides protection against fleas and ticks. Additionally, Livestock is predicted to grow at fastest CAGR during the forecast period owing to the growing livestock population, rising government initiatives, and surge in outbreak of diseases among cattle and sheep.
By route of administration, subcutaneous was the highest revenue-grossing segment in the global veterinary/animal vaccine market in 2022 owing to their benefits such as subcutaneous route of administration is quicker and less painful for animals. Additionally, intranasal is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of respiratory diseases in animals and increasing research & development activities by market players for the development of better vaccines, and growing introduction of new products. For instance, in February 2020, MSD Animal Health (Merck Animal Health) has recently introduced Nasalgen, an intranasal inoculation product designed to safeguard beef and dairy cattle against viral pathogens that cause pneumonia.
By end-user, veterinary clinics was the highest revenue-grossing segment in the global veterinary/animal vaccine market in 2022 owing to the increasing prevalence of infectious diseases among animals and rising initiatives by key market players such as mergers & acquisitions. For instance, in September 2022, Zoetis has completed the acquisition of Jurox, a privately-owned animal health company specializing in the development, manufacturing, and marketing of a diverse portfolio of veterinary medicines for the treatment of both livestock and companion animals. Additionally, veterinary hospitals is predicted to grow at fastest CAGR during the forecast period owing to the sure in number of pet owners visiting hospitals with their pets.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of livestock, increasing zoonotic diseases, presence of well-established pharmaceutical companies, rising cases of canine disorders, surge in adoption of vaccination for the same, growing pet population in the U.S., and increasing research & development activities. For instance, in February 2021, Ceva has formed a partnership with the French National Research Institute for Agriculture, Food, and Environment (INRAE) to conduct research and development in the field of preventing infectious diseases originating from animals and enhancing animal health. Additionally, Asia Pacific is predicted to grow at fastest CAGR during the forecast period owing to the increasing companion animal population, rising demand for animal-based products, growing adoption of veterinary vaccines, surge in government initiatives, increasing research & development expenditures, and rising introduction of new products. For instance, in November 2020, HIPRA Indonesia has recently conducted a virtual launch for GUMBOHATCH, an advanced immune complex immunization product for broiler chickens, designed to combat Infectious Bursal Disease.
Segmentation: Veterinary/Animal Vaccine Market Report 2022-2033
Veterinary/Animal Vaccine Market Analysis & Forecast By Product 2022-2033 (Revenue USD Bn)
- Subunit Vaccines
- Attenuated Live Vaccines
- Inactivated Vaccines
- Recombinant Vaccines
- DNA Vaccines
Veterinary/Animal Vaccine Market Analysis & Forecast By Animal 2022-2033 (Revenue USD Bn)
- Companion
- Feline
- Canine
- Others
- Livestock
- Aqua
- Poultry
- Swine
- Ruminants
Veterinary/Animal Vaccine Market Analysis & Forecast By Route of Administration Type 2022-2033 (Revenue USD Bn)
- Intramuscular
- Subcutaneous
- Intranasal
Veterinary/Animal Vaccine Market Analysis & Forecast By End-user 2022-2033 (Revenue USD Bn)
- Veterinary Clinics
- Veterinary Hospitals
- Pharmacies & Drug Stores
Veterinary/Animal Vaccine Market Analysis & Forecast by Region 2022-2033 (Revenue USD Bn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Veterinary/Animal Vaccine Market: Product Estimates & Trend Analysis
8. Veterinary/Animal Vaccine Market: Animal Estimates & Trend Analysis
9. Veterinary/Animal Vaccine Market: Route of Administration Estimates & Trend Analysis
10. Veterinary/Animal Vaccine Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Veterinary/Animal Vaccine Market
13. Europe Global Veterinary/Animal Vaccine Market
14. Asia Pacific Global Veterinary/Animal Vaccine Market
15. Latin America Global Veterinary/Animal Vaccine Market
16. MEA Global Veterinary/Animal Vaccine Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Zoetis
- Ceva Santé Animale
- Merck & Co. Inc.
- Vetoquinol S.A.
- Boehringer Ingelheim Gmbh
- Elanco
- Virbac
- Heska
- Dechra Pharmaceuticals Plc
- Idexx Laboratories Inc.
- Norbrook Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 12.95 Billion |
| Forecasted Market Value ( USD | $ 35.1 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
